209 related articles for article (PubMed ID: 35551405)
21. Direct oral anticoagulant (DOAC) versus low-molecular-weight heparin (LMWH) for the treatment of cancer-associated thrombosis (which agent for which patient).
Pernod G; Joly M; Sonnet B
J Med Vasc; 2020 Nov; 45(6S):6S17-6S23. PubMed ID: 33276939
[TBL] [Abstract][Full Text] [Related]
22. Equivalence of DOACS and LMWH for thromboprophylaxis after hip fracture surgery: Systematic review and meta-analysis.
Nederpelt CJ; Bijman Q; Krijnen P; Schipper IB
Injury; 2022 Mar; 53(3):1169-1176. PubMed ID: 34916036
[TBL] [Abstract][Full Text] [Related]
23. Therapeutic anticoagulation for venous thromboembolism after recent brain surgery: Evaluating the risk of intracranial hemorrhage.
de Melo Junior JO; Lodi Campos Melo MA; da Silva Lavradas LA; Ferreira Lopes PG; Luiz Ornelas II; de Barros PL; da Mata Pereira PJ; Niemeyer Filho P
Clin Neurol Neurosurg; 2020 Oct; 197():106202. PubMed ID: 32916398
[TBL] [Abstract][Full Text] [Related]
24. Anticoagulant therapy for acute venous thrombo-embolism in cancer patients: A systematic review and network meta-analysis.
Rossel A; Robert-Ebadi H; Combescure C; Grosgurin O; Stirnemann J; Addeo A; Garin N; Agoritsas T; Reny JL; Marti C
PLoS One; 2019; 14(3):e0213940. PubMed ID: 30897142
[TBL] [Abstract][Full Text] [Related]
25. Direct oral anticoagulants for cancer-associated venous thromboembolisms: a systematic review and network meta-analysis.
Samaranayake CB; Anderson J; McCabe C; Zahir SF; W Upham J; Keir G
Intern Med J; 2022 Feb; 52(2):272-281. PubMed ID: 32896977
[TBL] [Abstract][Full Text] [Related]
26. Comparison of the Safety of Prophylactic Anticoagulants After Intracranial Surgery.
Bell JS; Florence TJ; Phillips HW; Patel K; Macaluso NJ; Villanueva PG; Naik PK; Kim W
Neurosurgery; 2021 Aug; 89(3):527-536. PubMed ID: 34161594
[TBL] [Abstract][Full Text] [Related]
27. Efficacy and safety of direct oral anticoagulants vs. low molecular weight heparin for cancer-related venous thromboembolism: a meta-analysis of randomized trials.
Elbadawi A; Shnoda M; Mahmoud K; Elgendy IY
Eur Heart J Cardiovasc Pharmacother; 2021 Sep; 7(5):380-388. PubMed ID: 32556105
[TBL] [Abstract][Full Text] [Related]
28. OC-13 - Safe and effective use of direct oral anticoagulants (DOAC) versus conventional anticoagulation for the treatment of cancer-related venous thromboembolism.
Ross JA; Miller M; Hernandez CR
Thromb Res; 2016 Apr; 140 Suppl 1():S173-4. PubMed ID: 27161685
[TBL] [Abstract][Full Text] [Related]
29. Comparative effectiveness and safety of direct oral anticoagulants (DOACs) versus conventional anticoagulation for the treatment of cancer-related venous thromboembolism: A retrospective analysis.
Ross JA; Miller MM; Rojas Hernandez CM
Thromb Res; 2017 Feb; 150():86-89. PubMed ID: 28064037
[TBL] [Abstract][Full Text] [Related]
30. Is low-molecular-weight heparin safe for venous thromboembolism prophylaxis in patients with traumatic brain injury? A Western Trauma Association multicenter study.
Kwiatt ME; Patel MS; Ross SE; Lachant MT; MacNew HG; Ochsner MG; Norwood SH; Speier L; Kozar R; Gerber JA; Rowell S; Krishnakumar S; Livingston DH; Manis G; Haan JM
J Trauma Acute Care Surg; 2012 Sep; 73(3):625-8. PubMed ID: 22929493
[TBL] [Abstract][Full Text] [Related]
31. Comparative effectiveness of aspirin for symptomatic venous thromboembolism prophylaxis in patients undergoing total joint arthroplasty, a cohort study.
Sidhu V; Badge H; Churches T; Maree Naylor J; Adie S; A Harris I
BMC Musculoskelet Disord; 2023 Aug; 24(1):629. PubMed ID: 37537580
[TBL] [Abstract][Full Text] [Related]
32. Subcutaneous unfractionated heparin for the initial treatment of venous thromboembolism.
Robertson L; Strachan J
Cochrane Database Syst Rev; 2017 Feb; 2(2):CD006771. PubMed ID: 28195640
[TBL] [Abstract][Full Text] [Related]
33. Comparative effectiveness of direct oral anticoagulants versus low-molecular weight heparins for the prevention of venous thromboembolism after total hip or knee replacement: A nationwide database cohort study.
Blin P; Samama CM; Sautet A; Benichou J; Lignot-Maleyran S; Lamarque S; Lorrain S; Lassalle R; Droz-Perroteau C; Mismetti P; Moore N
Pharmacol Res; 2019 Mar; 141():201-207. PubMed ID: 30583081
[TBL] [Abstract][Full Text] [Related]
34. Trends in Anticoagulant Utilization and Clinical Outcomes for Cancer-Associated Thrombosis: A Multicenter Cohort Study in Thailand's Upper-Middle-Income Country Setting.
Kengkla K; Nathisuwan S; Sripakdee W; Saelue P; Sengnoo K; Sookprasert A; Subongkot S
JCO Glob Oncol; 2024 Feb; 10():e2300353. PubMed ID: 38422463
[TBL] [Abstract][Full Text] [Related]
35. The risk of intracranial hemorrhage in glioma patients receiving anticoagulant treatment for venous thromboembolism: a bayesian network meta-analysis.
Huo H; Shen S; Yang Y; Zhang H; Wu S; Bi T; Li Y
J Thromb Thrombolysis; 2023 Aug; 56(2):333-341. PubMed ID: 37341895
[TBL] [Abstract][Full Text] [Related]
36. Epidemiology, biology, and management of venous thromboembolism in gliomas: An interdisciplinary review.
Jo J; Diaz M; Horbinski C; Mackman N; Bagley S; Broekman M; Rak J; Perry J; Pabinger I; Key NS; Schiff D
Neuro Oncol; 2023 Aug; 25(8):1381-1394. PubMed ID: 37100086
[TBL] [Abstract][Full Text] [Related]
37. Direct oral anticoagulants vs. low-molecular-weight heparin for pulmonary embolism in patients with glioblastoma.
Dubinski D; Won SY; Voss M; Keil F; Miesbach W; Behmanesh B; Dosch M; Baumgarten P; Bernstock JD; Seifert V; Freiman TM; Gessler F
Neurosurg Rev; 2022 Feb; 45(1):451-457. PubMed ID: 33900495
[TBL] [Abstract][Full Text] [Related]
38. Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy.
Di Nisio M; Porreca E; Candeloro M; De Tursi M; Russi I; Rutjes AW
Cochrane Database Syst Rev; 2016 Dec; 12(12):CD008500. PubMed ID: 27906452
[TBL] [Abstract][Full Text] [Related]
39. Cabozantinib Safety With Different Anticoagulants in Patients With Renal Cell Carcinoma.
Shayeb AM; McManus HD; Urman D; Jani C; Zhang T; Dizman N; Meza L; Sivakumar A; Gan CL; Barata P; Bilen MA; Gao X; Heng D; Pal S; Narra R; Kilari D; Kaymakcalan MD; McGregor B; Choueiri TK; McKay RR
Clin Genitourin Cancer; 2023 Feb; 21(1):55-62. PubMed ID: 36411184
[TBL] [Abstract][Full Text] [Related]
40. Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy.
Di Nisio M; Porreca E; Otten HM; Rutjes AW
Cochrane Database Syst Rev; 2014 Aug; (8):CD008500. PubMed ID: 25171736
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
